Review
Immunology
Chrysoula G. Gialouri, Maria Pappa, Gerasimos Evangelatos, Elena Nikiphorou, George E. Fragoulis
Summary: Overweight and/or obese patients with inflammatory arthritis have lower chances of achieving and/or maintaining treatment targets. Weight/obesity also affects the response to TNF inhibitors in IA patients. A systematic literature review was conducted to evaluate the effect of weight/BMI on the efficacy of biologic and targeted-synthetic DMARDs for IA treatment.
AUTOIMMUNITY REVIEWS
(2023)
Article
Medicine, General & Internal
Ignacio Brana, Estefania Pardo, Stefanie Burger, Pablo Gonzalez del Pozo, Mercedes Alperi, Ruben Queiro
Summary: This study aimed to analyze the retention rate and safety of IXE in patients with PsA in routine clinical practice. The results showed that the retention rate of IXE was high in PsA patients and was consistently good regardless of age, gender, metabolic comorbidities, smoking status, or prior number of biologic therapies.
JOURNAL OF CLINICAL MEDICINE
(2023)
Review
Immunology
John Miller, Abin P. Puravath, Ana-Maria Orbai
Summary: Ixekizumab treatment in PsA was associated with a statistically significant higher risk of injection site reactions versus placebo or adalimumab. Ixekizumab had statistically significantly fewer serious adverse events than adalimumab. Ixekizumab demonstrated efficacy for all PsA disease activity domains as well as for slowing radiographic disease progression.
JOURNAL OF INFLAMMATION RESEARCH
(2021)
Review
Immunology
Eric Lespessailles, Hechmi Toumi
Summary: Psoriatic arthritis (PsA) is a chronic rheumatic disorder with various phenotypic features. IL-17 plays a critical role in the onset of PsA, and the monoclonal antibody Ixekizumab, targeting IL-17A, has shown promising efficacy and safety in PsA treatment.
Review
Medicine, General & Internal
Mengduan Pang, Zhe Sun, Hongfeng Zhang
Summary: This meta-analysis compared the risk of all-cause mortality between biological/targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs) and non-b/tsDMARDs in patients with rheumatoid arthritis (RA). The results showed that compared to non-b/tsDMARDs, antitumor necrosis factor therapy was associated with an increased risk of mortality.
Article
Rheumatology
Mikkel Ostergaard, Paul Bird, Chahin Pachai, Shuyan Du, Chun Wu, Jessica Landis, Thomas Fuerst, Harris A. Ahmad, Sean E. Connolly, Philip G. Conaghan
Summary: This study investigates the sensitivity to change of the OMERACT PsA MRI Scoring System in PsA patients receiving abatacept. The results show that abatacept treatment significantly reduces inflammatory components of the disease, as confirmed by MRI.
Article
Rheumatology
Imke Redeker, Katinka Albrecht, Joern Kekow, Gerd Ruediger Burmester, Juergen Braun, Martin Schaefer, Angela Zink, Anja Strangfeld
Summary: The study compared the occurrence of herpes zoster in patients with rheumatoid arthritis undergoing different treatments, showing a higher risk associated with targeted synthetic and biologic DMARDs.
ANNALS OF THE RHEUMATIC DISEASES
(2022)
Article
Rheumatology
Melissa L. Mannion, Fenglong Xie, Daniel B. Horton, Sarah Ringold, Colleen K. Correll, Anne Dennos, Timothy Beukelman
Summary: Biologic medications have greatly improved disease control and outcomes for patients with juvenile idiopathic arthritis (JIA), but a substantial number of patients may require switching to a second biologic. The time to switch has decreased in recent years, and further studies are needed to evaluate outcomes and optimal timing of biologic switching.
JOURNAL OF RHEUMATOLOGY
(2021)
Article
Rheumatology
Alvin F. Wells, Christopher J. Edwards, Alan J. Kivitz, Paul Bird, Benoit Guerette, Nikolay Delev, Maria Paris, Lichen Teng, Jacob A. Aelion
Summary: The study evaluated the long-term efficacy of Apremilast monotherapy in PsA patients over a period of 5 years. The results showed that Apremilast led to sustained improvement in PsA symptoms and signs, including reduction in joint swelling and tenderness. It was also effective in treating psoriasis. Apremilast was well tolerated throughout the study period.
Article
Medicine, General & Internal
Ippei Miyagawa, Shingo Nakayamada, Masanobu Ueno, Yusuke Miyazaki, Naoaki Ohkubo, Yoshino Inoue, Satoshi Kubo, Yoshiya Tanaka
Summary: This study validated the one-year effectiveness of precision medicine based on peripheral T-lymphocytic phenotyping in terms of DAPSA and MDA. The analysis of real-world clinical practice data showed variations in the impact on the immune system among bDMARDs.
FRONTIERS IN MEDICINE
(2022)
Review
Biochemistry & Molecular Biology
Maria Sofia Ciliento, Veronica Venturelli, Natale Schettini, Riccardo Bertola, Carlo Garaffoni, Giovanni Lanza, Roberta Gafa, Alessandro Borghi, Monica Corazza, Alen Zabotti, Sonia Missiroli, Caterina Boncompagni, Simone Patergnani, Mariasole Perrone, Carlotta Giorgi, Paolo Pinton, Marcello Govoni, Carlo Alberto Scire, Alessandra Bortoluzzi, Ettore Silvagni
Summary: The aim of this systematic literature review was to investigate the effects of b/tsDMARDs on the synovial membrane of PsA patients and identify biomarkers of response to therapy. A meta-analysis of 22 studies showed a significant reduction in CD3+ lymphocytes and CD68+ macrophages in synovial biopsies from patients treated with bDMARDs for 4-12 weeks. Reduction in CD3+ was correlated with clinical response. The most consistent finding in the literature was the reduction in CD3+/CD68+ sublining cells during the first 3 months of treatment with TNF inhibitors.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Medicine, General & Internal
Vandana Bhushan, Susan Lester, Liz Briggs, Raif Hijjawi, E. Michael Shanahan, Eliza Pontifex, Jem Ninan, Catherine Hill, Fin Cai, Jennifer Walker, Fiona Goldblatt, Mihir D. Wechalekar
Summary: Similar retention rates of the second and third compared to the first b/tsDMARD in RA, PsA, and AS support a differential b/tsDMARDs use strategy based on patient presentation. The risk of b/tsDMARD failure was halved in PsA patients, and covariates were not associated with the risk of bDMARD failure. The most common reason for switching was treatment failure.
FRONTIERS IN MEDICINE
(2021)
Article
Pharmacology & Pharmacy
Alina D. Lam, Enyuan Cao, Nathania Leong, Gracia Gracia, Christopher J. H. Porter, Orlagh M. Feeney, Natalie L. Trevaskis
Summary: Recent reports have emphasized the importance of the lymphatic system and immune cells in the development of inflammatory arthritis. Directing therapeutic drugs to the joint-draining lymphatics could improve treatment efficacy and reduce drug dosage. This study assessed the delivery of disease modifying anti-rheumatic drugs (DMARDs) to the lymphatics as a function of drug size and route of administration. The findings suggest that intra-articular injection of biologic DMARDs may provide a simple strategy to improve lymph and lymph node access and thus enhance the treatment of inflammatory arthritis.
EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS
(2022)
Article
Rheumatology
Bruce Kirkham, Carlos Sesin, Amanda M. Gellett, Aubrey T. Sprabery, Chen-Yen Lin, Anthony Turkiewicz
Summary: The study evaluated the efficacy of IXE in patients with PsA who did not respond adequately to one or two TNF inhibitors. The results showed that IXE improved the signs and symptoms of PsA in these difficult-to-treat patients, with significant improvements in various measures persisting through week 52.
Review
Immunology
Zhuqian Wang, Jie Huang, Duoli Xie, Dongyi He, Aiping Lu, Chao Liang
Summary: Despite significant efforts to overcome treatment failure in rheumatoid arthritis, including identifying biomarkers, exploring reasons for loss of efficacy, developing sequential or combinational DMARD strategies, and approving new DMARDs, specific recommendations for individual patients are still lacking, prompting the potential of precision medicine for personalized disease management using cutting-edge technologies and big data.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Dermatology
Lisa A. Beck, Diamant Thaci, Mette Deleuran, Marjolein de Bruin-Weller, Zhen Chen, Faisal A. Khokhar, Meng Zhang, Zafer E. Ozturk, Brad Shumel
Summary: The study found that adults with moderate-to-severe AD treated with dupilumab for up to 3 years did not experience clinically significant changes in mean laboratory parameters, indicating that continuous long-term use of the treatment is supported without the need for laboratory monitoring.
JOURNAL OF DERMATOLOGICAL TREATMENT
(2022)
Article
Dermatology
D. Thaci, K. Eyerich, A. Pinter, M. Sebastian, K. Unnebrink, S. Rubant, D. A. Williams, P. Weisenseel
Summary: This study found that risankizumab was superior to FAEs in treating psoriasis, providing earlier and greater improvement in outcomes that persisted with continued treatment. Risankizumab also showed more favorable safety results with no new safety signals observed for either treatment arm.
BRITISH JOURNAL OF DERMATOLOGY
(2022)
Article
Dermatology
Andrew Blauvelt, April W. Armstrong, Richard G. Langley, Kurt Gebauer, Diamant Thaci, Jerry Bagel, Lyn C. Guenther, Carle Paul, Bruce Randazzo, Susan Flavin, Ming-Chun Hsu, Yin You, Kristian Reich
Summary: In this study, guselkumab showed superior efficacy compared to secukinumab at week 48 in treating patients with moderate-to-severe plaque psoriasis, across various baseline characteristics. The largest differences in efficacy were observed in patients aged 65 and older, as well as in patients weighing over 100 kg.
JOURNAL OF DERMATOLOGICAL TREATMENT
(2022)
Review
Dermatology
James Krueger, Lluis Puig, Diamant Thaci
Summary: Generalized pustular psoriasis (GPP) is a rare and severe skin disorder without approved specific therapies. Current treatment options are based on limited evidence and recent advances have identified potential targets for targeted therapy based on improved understanding of the disease mechanisms and gene mutations associated with GPP.
AMERICAN JOURNAL OF CLINICAL DERMATOLOGY
(2022)
Article
Rheumatology
Eugen Feist, Xenofon Baraliakos, Frank Behrens, Diamant Thaci, Thilo Klopsch, Anja Plenske, Lisa K. Blindzellner, Pascal Klaus, Thomas Meng, Peter-Andreas Loeschmann
Summary: This study investigated the proportion of German patients with rheumatoid arthritis who achieved remission or low disease activity after 12 and 24 weeks of etanercept treatment. It found that a considerable proportion of patients attained their treatment targets after 12 weeks, and the proportion further increased with longer treatment duration.
RHEUMATOLOGY AND THERAPY
(2022)
Article
Dermatology
Diamant Thaci, Ron Vender, Menno A. de Rie, Curdin Conrad, David M. Pariser, Bruce Strober, Veerle Vanvoorden, Maggie Wang, Cynthia Madden, Dirk de Cuyper, Alexa B. Kimball
Summary: The clinical and health-related quality of life responses observed during the first 16 weeks of BE SURE were sustained over 2 years of treatment, regardless of bimekizumab maintenance dosing. Switching from adalimumab to bimekizumab also resulted in sustained improvements up to Week 104. Bimekizumab had a good safety profile with no new safety signals.
BRITISH JOURNAL OF DERMATOLOGY
(2023)
Article
Dermatology
Thomas Bieber, Norito Katoh, Eric L. Simpson, Marjolein de Bruin-Weller, Diamant Thaci, Antonio Torrelo, Angelina Sontag, Susanne Grond, Maher Issa, Xiaoyu Lu, Tracy Cardillo, Katrin Holzwarth, Jacob P. Thyssen
Summary: Baricitinib demonstrated a consistent safety profile in the long-term treatment of atopic dermatitis patients, with no new safety signals identified. The incidence rates of major adverse cardiovascular events, deep vein thromboses/pulmonary emboli, malignancies, and serious infections were within the ranges observed in the background population of patients with AD.
JOURNAL OF DERMATOLOGICAL TREATMENT
(2023)
Article
Dermatology
Matthias Augustin, Andrea Bauer, Konstantin Ertner, Ralph von Kiedrowski, Florian Schenck, Jutta Ramaker-Brunke, Sophie Moeller, Anja Fait, Mike Bastian, Diamant Thaci
Summary: The PROLEAD study examined the effectiveness and safety of dupilumab in real-world clinical practice for patients with moderate-to-severe atopic dermatitis (AD). The results showed that dupilumab was more effective and well tolerated in a real-world setting compared to phase 3 clinical trials.
DERMATOLOGY AND THERAPY
(2023)
Article
Dermatology
Mark G. Lebwohl, Joseph F. Merola, Katelyn Rowland, Megan Miller, Ya-Wen Yang, Jenny Yu, Yin You, Daphne Chan, Diamant Thaci, Richard G. Langley
Summary: This study evaluated the safety of guselkumab in 2891 patients with psoriasis who were treated for up to 5 years. The findings showed that guselkumab demonstrated favorable safety, consistent with previous reports. The safety event rates in guselkumab-treated patients were similar to those observed in the placebo group and remained consistent throughout long-term treatment.
BRITISH JOURNAL OF DERMATOLOGY
(2023)
Letter
Dermatology
Andrew Blauvelt, Diamant Thaci, Kim A. Papp, Vincent Ho, Kamran Ghoreschi, Byung Soo Kim, Megan Miller, Yaung-Kaung Shen, Yin You, Daphne Chan, Jenny Yu, Ya-Wen Yang, Mark G. Lebwohl, Alice B. Gottlieb, Jeffrey Crowley, Peter Foley
BRITISH JOURNAL OF DERMATOLOGY
(2023)
Article
Dermatology
A. D. Burden, Y. Okubo, M. Zheng, D. Thaci, P. van de Kerkhof, N. Hu, M. Quaresma, C. Thoma, S. E. Choon
Summary: Effisayil 1 was a study investigating the use of spesolimab in patients with a flare-up of generalized pustular psoriasis (GPP). The study found that patients receiving spesolimab showed rapid clearance of pustules and skin symptoms within 1 week. The effectiveness and safety of spesolimab were consistent across different patient demographic and clinical characteristics.
EXPERIMENTAL DERMATOLOGY
(2023)
Article
Dermatology
Nina Magnolo, Thomas Jaenicke, Athanasios Tsianakas, Wolfgang Czech, Diamant Thaci, Andreas Pinter, Delphine Kerob, Samir Salah, Thomas A. Luger
Summary: This study aimed to investigate the efficacy of skin care products containing emollients and a syndet with the ability to improve skin barrier and microbiome in moderate to severe AD patients. The results showed that patients using this product had significant improvements in itchiness and quality of life after 10 weeks, while using 23% less product compared to the control group.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
(2023)
Review
Biochemistry & Molecular Biology
Henning Olbrich, Christian D. Sadik, Ralf J. Ludwig, Diamant Thaci, Katharina Boch
Summary: Dupilumab, approved for atopic dermatitis and prurigo nodularis, has shown effectiveness in treating various dermatologic diseases including bullous autoimmune diseases, eczema, prurigo, and alopecia areata.
Correction
Rheumatology
Eugen Feist, Xenofon Baraliakos, Frank Behrens, Diamant Thaci, Thilo Klopsch, Anja Plenske, Lisa K. Blindzellner, Pascal Klaus, Thomas Meng, Peter-Andreas Loeschmann
RHEUMATOLOGY AND THERAPY
(2023)
Article
Oncology
Kim A. Papp, Mark G. Lebwohl, Diamant Thaci, Janusz Jaworski, Bartlomiej Kwiek, Jakub Trefler, Anna Dudek, Jacek C. Szepietowski, Nataliya Reznichenko, Joanna Narbutt, Wojciech Baran, Joanna Kolinek, Stefan Daniluk, Katarzyna Bartnicka-Maslowska, Adam Reich, Yuriy Andrashko, Sunghyun Kim, Yunju Bae, Dabee Jeon, Jinsun Jung, Hyunseung Lee, Tina Pyo, Woori Ko
Summary: CT-P43 demonstrated equivalent efficacy to originator ustekinumab in adults with moderate to severe plaque psoriasis, with comparable pharmacokinetic, safety, and immunogenicity profiles.